This is NOT the End for Immunotherapy in Parkinson's Disease - A Perspective from Early Drug Development Scientists.

Brundin, Patrik; Svoboda, Hanno; Bonni, Azad; Pagano, Gennaro

Brundin, Patrik; Svoboda, Hanno; Bonni, Azad; Pagano, Gennaro.

Affiliation

Brundin P; Neuroscience and Rare Diseases, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Roche Ltd, Basel, Switzerland.
Svoboda H; Neuroscience and Rare Diseases, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Roche Ltd, Basel, Switzerland.
Bonni A; Roche Diagnostics GmbH, Penzberg, Germany.
Pagano G; Neuroscience and Rare Diseases, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Roche Ltd, Basel, Switzerland.

J Parkinsons Dis ; 12(8): 2293-2296, 2022.

Article de En | MEDLINE | ID: mdl-36404558

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Maladie de Parkinson Limites: Humans Langue: En Journal: J Parkinsons Dis Année: 2022 Type de document: Article Pays d'affiliation: Suisse

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google